Presentation Description: For COVID-19 and beyond, we must adapt for a future where drugs and bioanalytical assays must be developed rapidly. We will discuss how adopting more biomarkers, in vitro assays, and novel technologies such as recombinant antibodies can shorten assay development time. We will demonstrate how we generated recombinant antibody libraries for COVID-19 antibody assays to shorten the time needed to develop antibodies in animals while maintaining data quality. We also developed in vitro assays, such as one to detect antibody dependent enhancement, rapidly using novel technologies. We used non-replicating reporter viral particles (RVPs) that infect cells if non-neutralizing antibodies are present. These RVPs accelerated assay development and negated the need for BSL-3 laboratories. Finally, we will advocate for biomarkers to shorten the time needed for vaccine trials similar to CD4/CD8 ratios in HIV trials. While the current pandemic carries challenges, these technologies will make drug development more efficient.
list technologies that can be used to shorten assay development time for infectious diseases, antibodies, and vaccines.
describe the benefits and challenges of using recombinant antibodies for SARS-CoV-2 antibody assays.
understand the utility of in vitro assays and biomarkers in shortening the time needed for vaccine trials.